Solid-state Protein Formulations

References

• Chang BS Yeung B . Physical stability of protein pharmaceuticals. In : Formulation and Process Development Strategies for Manufacturing Biopharmaceuticals.JameelFHershensonS ( Eds.). John Wiley & Sons, Inc., Hoboken, NJ, USA, 69–104 (2010).
   Google Scholar
• Santucci R Sinibaldi F Fiorucci L . Protein folding, unfolding and misfolding: role played by intermediate states. Mini Rev. Med. Chem.8 (1), 57–62 (2008).
   PubMed Web of Science ®Google Scholar
• Creighton T . Protein folding. Biochem. J.270 (1), 1–16 (1990).
   PubMed Web of Science ®Google Scholar
• Dill KA MacCallum JL . The protein-folding problem, 50 years on. Science338 (6110), 1042–1046 (2012).
   PubMed Web of Science ®Google Scholar
• Onuchic JN Wolynes PG . Theory of protein folding. Curr. Opin. Struct. Biol.14 (1), 70–75 (2004).
   PubMed Web of Science ®Google Scholar
• Frokjaer S Otzen DE . Protein drug stability: a formulation challenge. Nat. Rev. Drug Discov.4 (4), 298–306 (2005).
   PubMed Web of Science ®Google Scholar
• Manning MC Patel K Borchardt RT . Stability of protein pharmaceuticals. Pharm. Res.6 (11), 903–918 (1989).
   PubMed Web of Science ®Google Scholar
• Ferreira ST De Felice FG Chapeaurouge A . Metastable, partially folded states in the productive folding and in the misfolding and amyloid aggregation of proteins. Cell Biochem. Biophys.44 (3), 539–548 (2006).
   PubMed Web of Science ®Google Scholar
• Neudecker P Robustelli P Cavalli A et al. Structure of an intermediate state in protein folding and aggregation. Science336 (6079), 362–366 (2012).
   PubMed Web of Science ®Google Scholar
• Calamai M Canale C Relini A Stefani M Chiti F Dobson CM . Reversal of protein aggregation provides evidence for multiple aggregated States. J. Mol. Biol.346 (2), 603–616 (2005).
   PubMed Web of Science ®Google Scholar
• Manning MC Chou DK Murphy BM Payne RW Katayama DS . Stability of protein pharmaceuticals: an update. Pharm. Res.27 (4), 544–575 (2010).
   PubMed Web of Science ®Google Scholar
• Wang W Singh SK Li N Toler MR King KR Nema S . Immunogenicity of protein aggregates‐‐concerns and realities. Int. J. Pharm.431 (1–2), 1–11 (2012).
   PubMedGoogle Scholar
• Park J Nagapudi K Vergara C Ramachander R Laurence JS Krishnan S . Effect of pH and excipients on structure, dynamics, and long-term stability of a model IgG1 monoclonal antibody upon freeze-drying. Pharm. Res.30 (4), 968–984 (2013).
   PubMed Web of Science ®Google Scholar
• Wang W Nema S Teagarden D . Protein aggregation‐‐pathways and influencing factors. Int. J. Pharm.390 (2), 89–99 (2010).
   PubMed Web of Science ®Google Scholar
• Liu L Braun LJ Wang W Randolph TW Carpenter JF . Freezing-induced perturbation of tertiary structure of a monoclonal antibody. J. Pharm. Sci.103 (7), 1979–1986 (2014).
   PubMed Web of Science ®Google Scholar
• Li W Zhou R Mu Y . Salting effects on protein components in aqueous NaCl and urea solutions: toward understanding of urea-induced protein denaturation. J. Phys. Chem. B.116 (4), 1446–1451 (2012).
   PubMed Web of Science ®Google Scholar
• Monera OD Kay CM Hodges RS . Protein denaturation with guanidine hydrochloride or urea provides a different estimate of stability depending on the contributions of electrostatic interactions. Protein Sci.3 (11), 1984–1991 (1994).
   PubMed Web of Science ®Google Scholar
• Mahler H-C Friess W Grauschopf U Kiese S . Protein aggregation: pathways, induction factors and analysis. J. Pharm. Sci.98 (9), 2909–2934 (2009).
   PubMed Web of Science ®Google Scholar
• Liu J Nguyen MDH Andya JD Shire SJ . Reversible self-association increases the viscosity of a concentrated monoclonal antibody in aqueous solution. J. Pharm. Sci.94 (9), 1928–1940 (2005).
   PubMed Web of Science ®Google Scholar
• Wang W . Protein aggregation and its inhibition in biopharmaceutics. Int. J. Pharm.289 (1–2), 1–30 (2005).
   PubMed Web of Science ®Google Scholar
• Hermeling S Crommelin DJA Schellekens H Jiskoot W . Structure-immunogenicity relationships of therapeutic proteins. Pharm. Res.21 (6), 897–903 (2004).
   PubMed Web of Science ®Google Scholar
• Rosenberg AS . Effects of protein aggregates: an immunologic perspective. AAPS J.8 (3), E501–E507 (2006).
   PubMed Web of Science ®Google Scholar
• Stefani M Dobson CM . Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. J. Mol. Med.81 (11), 678–699 (2003).
   PubMed Web of Science ®Google Scholar
• Kamerzell TJ Esfandiary R Joshi SB Middaugh CR Volkin DB . Protein-excipient interactions: mechanisms and biophysical characterization applied to protein formulation development. Adv. Drug Deliv. Rev.63 (13), 1118–1159 (2011).
   PubMed Web of Science ®Google Scholar
• Jeong SH . Analytical methods and formulation factors to enhance protein stability in solution. Arch. Pharm. Res.35 (11), 1871–1886 (2012).
   PubMed Web of Science ®Google Scholar
• Maddux NR Joshi SB Volkin DB Ralston JP Middaugh CR . Multidimensional methods for the formulation of biopharmaceuticals and vaccines. J. Pharm. Sci.100 (10), 4171–4197 (2011).
   PubMed Web of Science ®Google Scholar
• Krishnan S Pallitto M Ricci M . Development of formulations for therapeutic monoclonal antibodies and Fc fusion proteins. In : Formulation and Process Development Strategies for Manufacturing Biopharmaceuticals.JameelFHershensonS ( Eds.). John Wiley & Sons Inc., Hoboken, NJ, USA, 383–428 (2010).
   Google Scholar
• Sundaramurthi P Suryanarayanan R . Calorimetry and complementary techniques to characterize frozen and freeze-dried systems. Adv. Drug Deliv. Rev.64 (5), 384–395 (2012).
   PubMed Web of Science ®Google Scholar
• Topp EM Zhang L Zhao H Payne RW Evans GJ Manning MC . Chemical instability in peptide and protein pharmaceuticals. In : Formulation and Process Development Strategies for Manufacturing Biopharmaceuticals.JameelFHershensonS ( Eds.). John Wiley & Sons, Inc., Hoboken, NJ, USA, 41–67 (2010).
   Google Scholar
• Andya JD Hsu CC Shire SJ . Mechanisms of aggregate formation and carbohydrate excipient stabilization of lyophilized humanized monoclonal antibody formulations. AAPS PharmSci.5 (2), 21–31 (2003).
   Google Scholar
• Franks F . Freeze-drying of bioproducts: putting principles into practice. Eur. J. Pharm. Biopharm.45 (3), 221–229 (1998).
   PubMed Web of Science ®Google Scholar
• Carpenter JF Pikal MJ Chang BS Randolph TW . Rational design of stable lyophilized protein formulations: some practical advice. Pharm. Res.14 (8), 969–975 (1997).
   PubMed Web of Science ®Google Scholar
• Gaisford S Saunders M . Physical forms I-Crystalline materials. In : Essentials of Pharmaceutical Preformulation.John Wiley & Sons Inc., West Sussex, 127–155 (2013).
   Google Scholar
• Shenoy B Wang Y Shan W Margolin AL . Stability of crystalline proteins. Biotechnol. Bioeng.73 (5), 358–369 (2001).
   PubMed Web of Science ®Google Scholar
• Basu SK Govardhan CP Jung CW Margolin AL . Protein crystals for the delivery of biopharmaceuticals. Expert Opin. Biol. Ther.4 (3), 301–317 (2004).
   PubMed Web of Science ®Google Scholar
• Chayen NE Saridakis E . Protein crystallization: from purified protein to diffraction-quality crystal. Nat. Method.5 (2), 147–153 (2008).
   PubMed Web of Science ®Google Scholar
• Feher G Kam Z . Nucleation and growth of protein crystals: general principles and assays. Methods Enzymol.114, 77–112 (1985).
   PubMed Web of Science ®Google Scholar
• Bertrand G Macheboeuf M . The influence of nickel and cobalt on the effect exerted by insulin in a rabbit. Science64, 629–630 (1926).
   PubMedGoogle Scholar
• Lutz RE . The normal occurrence of zinc in biologic materials: a review of the literature, and a study of the normal distribution of zinc in the rat, cat, and man. J. Ind. Hygiene8, 177 (1926).
   Google Scholar
• Baker E Blundell T Cutfield J et al. The structure of 2Zn pig insulin crystals at 1.5 A resolution. Philos. Trans. R. Soc. Lond. B. Biol. Sci.319, 369–456 (1988).
   PubMed Web of Science ®Google Scholar
• Smith G Pangborn W Blessing R . The structure of T6 human insulin at 1.0 A resolution. Acta Crystallogr. Sect. D Biol. Crystallogr.59, 474–482 (2003).
   PubMedGoogle Scholar
• Whittingham JL Chaudhuri S Dodson EJ Moody PC Dodson GG . X-ray crystallographic studies on hexameric insulins in the presence of helix-stabilizing agenst, thiocyanate, methylparaben and phenol. Biochemistry34, 15553–15563 (1995).
   PubMed Web of Science ®Google Scholar
• Smith GD Dodson GG . Structure of a rhombohedral R6 insulin/phenol complex. Proteins14, 401–408 (1992).
   PubMed Web of Science ®Google Scholar
• Shi K Bi H Jiang Y . Characterization of physiochemical and biological properties of spherical protein crystals for sustained release. Asian J. Pharm. Sci.8 (1), 58–63 (2013).
   Google Scholar
• Hebel D Huber S Stanislawski B Hekmat D . Stirred batch crystallization of a therapeutic antibody fragment. J. Biotechnol.166, 206–211 (2013).
   PubMed Web of Science ®Google Scholar
• Nanev CN . How do crystal lattice contacts reveal protein crystallization mechanism?Cryst. Res. Technol.43 (9), 914–920 (2008).
   Web of Science ®Google Scholar
• Nanev CN . Protein crystal nucleation: Recent notions. Cryst. Res. Technol.42 (1), 4–12 (2007).
   Web of Science ®Google Scholar
• Northrup SH Erickson HP . Kinetics of protein-protein association explained by Brownian dynamics computer simulation. Proc. Natl Acad. Sci. USA89 (8), 3338–3342 (1992).
   PubMed Web of Science ®Google Scholar
• Wukovitz S Yeates T . Why protein crystals favour some space-groups over others. Nat. Struc. Biol.2, 1062–1067 (1995).
   PubMedGoogle Scholar
• Nanev CN . Protein crystal nucleation: Recent notions. Crystal Res. Tech.12 (1), 4–12 (2007).
   Google Scholar
• Nanev CN . Kinetics and intimate mechanism of protein crystal nucleation. Prog. Cryst. Growth Charact. Mater.59 (4), 133–169 (2013).
   Web of Science ®Google Scholar
• Huus K Havelund S Olsen HB van de Wert M Frokjaer S . Chemical and thermal stability of insulin: effects of zinc and ligand binding to the insulin zinc-hexamer. Pharm. Res.23 (11), 2611–2620 (2006).
   PubMed Web of Science ®Google Scholar
• Owens DR Zinman B Bolli GB . Insulins today and beyond. Lancet358 (9283), 739–46 (2001).
   PubMed Web of Science ®Google Scholar
• Walsh G . Therapeutic insulins and their large-scale manufacture. Appl. Microbiol. Biotechnol.67 (2), 151–159 (2005).
   PubMed Web of Science ®Google Scholar
• Jonassen I Havelund S Jensen T Steensgaard D Wahlund P Ribel U . Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm. Res.29, 2104–2114 (2012).
   PubMed Web of Science ®Google Scholar
• Krayenbuhl C Rosenberg T . Crystalline protamine insulin. Rep. Steno. Mem. Hosp. Nord. Insul.1, 60–73 (1946).
   Google Scholar
• Hoffmann J Chance R Johnson M . Purification and analysis of the major components of chum salmon protamine contained in insulin formulations using high-performance liquid chromatography. Protein Expr. Purif.1 (2), 127–133 (1990).
   PubMedGoogle Scholar
• Balschimidt P Hansen F Dodson E Dodson G Kober F . Structure of porcine insulin cocrystallized with clupeine-z. Acta Crystallogr. B47, 975–986 (1991).
   PubMedGoogle Scholar
• Norrman M Hubálek F Schluckebier G . Structural characterization of insulin NPH formulations. Eur. J. Pharm. Sci.30 (5), 414–423 (2007).
   PubMed Web of Science ®Google Scholar
• Hirsch I . Insulin analogues. N. Engl. J. Med.352, 174–183 (2005).
   PubMed Web of Science ®Google Scholar
• Barnett A Owens D . Insulin analogues. Lancet349 (9044), 47–51 (1997).
   PubMed Web of Science ®Google Scholar
• Gough SCL Harris S Woo V Davies M . Insulin degludec: overview of a novel ultra long-acting basal insulin. Diabetes. Obes. Metab.15 (4), 301–309 (2013).
   PubMed Web of Science ®Google Scholar
• Jameel F Pikal M . Design of a formulation for freeze drying. In : Formulation and Process Development Strategies for Manufacturing Biopharmaceuticals.JameelFHershensonS ( Eds.). John Wiley & Sons, Inc., Hoboken, NJ, USA, 457–492 (2010).
   Google Scholar
• Cheung MS García AE Onuchic JN . Protein folding mediated by solvation: water expulsion and formation of the hydrophobic core occur after the structural collapse. Proc. Natl Acad. Sci. USA99 (2), 685–690 (2002).
   PubMed Web of Science ®Google Scholar
• Crommelin DJ . Formulation of biotech products, including biopharmaceutical considerations. In : Pharmaceutical Biotechnology.CrommelinDJASindelarRDMeibohmB ( Eds.). Springer, New York, USA, 67–123 (2008).
   Google Scholar
• Kasper JC Friess W . The freezing step in lyophilization: physico-chemical fundamentals, freezing methods and consequences on process performance and quality attributes of biopharmaceuticals. Eur. J. Pharm. Biopharm.78 (2), 248–63 (2011).
   PubMed Web of Science ®Google Scholar
• Wang W . Lyophilization and development of solid protein pharmaceuticals. Int. J. Pharm.203 (1–2), 1–60 (2000).
   PubMed Web of Science ®Google Scholar
• Heller MC Carpenter JF Randolph TW . Protein formulation and lyophilization cycle design: Prevention of damage due to freeze‐concentration induced phase separation. Biotechnol. Bioeng.63 (2), 166–174 (1999).
   PubMed Web of Science ®Google Scholar
• Tang X Pikal MJ . Design of freeze-drying processes for pharmaceuticals: practical advice. Pharm. Res.21 (2), 191–200 (2004).
   PubMed Web of Science ®Google Scholar
• Colandene JD Maldonado LM Creagh AT Vrettos JS Goad KG Spitznagel TM . Lyophilization cycle development for a high-concentration monoclonal antibody formulation lacking a crystalline bulking agent. J. Pharm. Sci.96 (6), 1598–1608 (2007).
   PubMed Web of Science ®Google Scholar
• Franks F Auffret T . Freeze-drying of pharmaceuticals and biopharmaceuticals : Principles and Practice.Royal Society of Chemistry, London, UK (2007).
   Google Scholar
• Chang LL Pikal MJ . Mechanisms of protein stabilization in the solid state. J. Pharm. Sci.98 (9), 2886–2908 (2009).
   PubMed Web of Science ®Google Scholar
• Eckhardt BM Oeswein JQ Bewley TA . Effect of freezing on aggregation of human growth hormone. Pharm. Res.8 (11), 1360–1364 (1991).
   PubMed Web of Science ®Google Scholar
• Strambini GB Gabellieri E . Proteins in frozen solutions: evidence of ice-induced partial unfolding. Biophys. J.70 (2), 971–976 (1996).
   PubMed Web of Science ®Google Scholar
• Bhatnagar BS Bogner RH Pikal MJ . Protein stability during freezing: separation of stresses and mechanisms of protein stabilization. Pharm. Dev. Technol.12 (5), 505–523 (2007).
   PubMed Web of Science ®Google Scholar
• Ohtake S Kita Y Arakawa T . Interactions of formulation excipients with proteins in solution and in the dried state. Adv. Drug Deliv. Rev.63 (13), 1053–1073 (2011).
   PubMed Web of Science ®Google Scholar
• Crowe JH Hoekstra FA Crowe LM . Anhydrobiosis. Annu. Rev. Physiol.54 (1), 579–599 (1992).
   PubMedGoogle Scholar
• Fox K . Biopreservation. Putting proteins under glass. Science267 (5206), 1922–1923 (1995).
   PubMed Web of Science ®Google Scholar
• Carpenter JF Crowe JH . An infrared spectroscopic study of the interactions of carbohydrates with dried proteins. Biochemistry.28 (9), 3916–3922 (1989).
   PubMed Web of Science ®Google Scholar
• Prestrelski SJ Arakawa T Carpenter JF . Separation of freezing- and drying-induced denaturation of lyophilized proteins using stress-specific stabilization. II. Structural studies using infrared spectroscopy. Arch. Biochem. Biophys.303 (2), 465–473 (1993).
   PubMed Web of Science ®Google Scholar
• Prestrelski SJ Pikal KA Arakawa T . Optimization of lyophilization conditions for recombinant human interleukin-2 by dried-state conformational analysis using Fourier-transform infrared spectroscopy. Pharm. Res.12 (9), 1250–1259 (1995).
   PubMed Web of Science ®Google Scholar
• Nema S Avis KE . Freeze-thaw studies of a model protein, lactate dehydrogenase, in the presence of cryoprotectants. J. Parenter. Sci. Technol.47 (2), 76–83 (1993).
   PubMedGoogle Scholar
• Dawson PJ . Effect of formulation and freeze-drying on the long-term stability of rDNA-derived cytokines. Dev. Biol. Stand.74, 273–282 (1992).
   PubMedGoogle Scholar
• Anchordoquy TJ Carpenter JF . Polymers protect lactate dehydrogenase during freeze-drying by inhibiting dissociation in the frozen state. Arch. Biochem. Biophys.332 (2), 231–238 (1996).
   PubMed Web of Science ®Google Scholar
• Allison SD Randolph TW Manning MC Middleton K Davis A Carpenter JF . Effects of drying methods and additives on structure and function of actin: mechanisms of dehydration-induced damage and its inhibition. Arch. Biochem. Biophys.358 (1), 171–181 (1998).
   PubMed Web of Science ®Google Scholar
• Skrabanja AT de Meere AL de Ruiter RA van den Oetelaar PJ . Lyophilization of biotechnology products. PDA J. Pharm. Sci. Technol.48 (6), 311–317 (1994).
   PubMedGoogle Scholar
• Kreilgaard L Frokjaer S Flink JM Randolph TW Carpenter JF . Effects of additives on the stability of recombinant human factor XIII during freeze-drying and storage in the dried solid. Arch. Biochem. Biophys.360 (1), 121–134 (1998).
   PubMed Web of Science ®Google Scholar
• Izutsu K-I Yoshioka S Kojima S . Increased stabilizing effects of amphiphilic excipients on freeze-drying of lactate dehydrogenase (LDH) by dispersion into sugar matrices. Pharm. Res.12 (6), 838–843 (1995).
   PubMed Web of Science ®Google Scholar
• Carpenter JF Prestrelski SJ Arakawa T . Separation of freezing-and drying-induced denaturation of lyophilized proteins using stress-specific stabilization: I. Enzyme activity and calorimetric studies. Arch. Biochem. Biophys.303 (2), 456–464 (1993).
   PubMed Web of Science ®Google Scholar
• Bhatnagar BS Martin SM Teagarden DL Shalaev EY Suryanarayanan R . Investigation of PEG crystallization in frozen PEG-sucrose-water solutions: II. Characterization of the equilibrium behavior during freeze-thawing. J. Pharm. Sci.99 (11), 4510–4524 (2010).
   PubMed Web of Science ®Google Scholar
• Jameel F Hershenson S . Formulation and Process Development Strategies for Manufacturing Biopharmaceuticals (1st Edition).John Wiley & Sons Inc., Hoboken, NJ, USA (2010).
   Google Scholar
• Chang BS Kendrick BS Carpenter JF . Surface-induced denaturation of proteins during freezing and its inhibition by surfactants. J. Pharm. Sci.85 (12), 1325–1330 (1996).
   PubMed Web of Science ®Google Scholar
• Mumenthaler M Hsu CC Pearlman R . Feasibility study on spray-drying protein pharmaceuticals: Recombinant human growth hormone and tissue-type plasminogen activator. Pharm. Res.11 (1), 12–20 (1994).
   PubMed Web of Science ®Google Scholar
• Pikal-Cleland KA Rodríguez-Hornedo N Amidon GL Carpenter JF . Protein denaturation during freezing and thawing in phosphate buffer systems: monomeric and tetrameric β-galactosidase. Arch. Biochem. Biophys.384 (2), 398–406 (2000).
   PubMed Web of Science ®Google Scholar
• Pikal-Cleland KA Carpenter JF . Lyophilization-induced protein denaturation in phosphate buffer systems: monomeric and tetrameric beta-galactosidase. J. Pharm. Sci.90 (9), 1255–1268 (2001).
   PubMed Web of Science ®Google Scholar
• Pikal-Cleland KA Cleland JL Anchordoquy TJ Carpenter JF . Effect of glycine on pH changes and protein stability during freeze-thawing in phosphate buffer systems. J. Pharm. Sci.91 (9), 1969–1979 (2002).
   PubMed Web of Science ®Google Scholar
• Wang W Singh S Zeng DL King K Nema S . Antibody structure, instability, and formulation. J. Pharm. Sci.96 (1), 1–26 (2006).
   Web of Science ®Google Scholar
• Cleland JL Powell MF Shire SJ . The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation. Crit. Rev. Ther. Drug Carrier Syst.10 (4), 307–377 (1993).
   PubMed Web of Science ®Google Scholar
• Daugherty AL Mrsny RJ . Formulation and delivery issues for monoclonal antibody therapeutics. Adv. Drug Deliv. Rev.58 (5–6), 686–706 (2006).
   PubMed Web of Science ®Google Scholar
• Chang LL Shepherd D Sun J et al. Mechanism of protein stabilization by sugars during freeze-drying and storage: native structure preservation, specific interaction, and/or immobilization in a glassy matrix? J. Pharm. Sci. 94 (7), 1427–1444 (2005).
   PubMed Web of Science ®Google Scholar
• Campos E Branquinho J Carreira AS Carvalho A Coimbra P Ferreira C . Designing polymeric microparticles for biomedical and industrial applications. European Polymer Journal49 (8), 2005–2021 (2013).
   Web of Science ®Google Scholar
• Abdul-Fattah AM Kalonia DS Pikal MJ . The challenge of drying method selection for protein pharmaceuticals: product quality implications. J. Pharm. Sci.96 (8), 1886–1916 (2007).
   PubMed Web of Science ®Google Scholar
• Prinn K Constantino HR Tracy M . Statistical modeling of protein spray drying at the lab scale. AAPS PharmSciTech.3 (1) (2002).
   PubMedGoogle Scholar
• Ståhl K Claesson M Lilliehorn P Linden H Backstrom K . The effect of process variables on the degradation and physical properties of spray dried insulin intended for inhalation. Int. J. Pharm.233, 227–237 (2002).
   PubMed Web of Science ®Google Scholar
• Banga A . Therapeutic Peptides and Proteins: Formulation, Processing and Delivery Systems (2nd Edition).CRC Press, FL (2006).
   Google Scholar
• Abdul-Fattah AM Lechuga-Ballesteros D Kalonia DS Pikal MJ . The impact of drying method and formulation on the physical properties and stability of methionyl human growth hormone in the amorphous solid state. J. Pharm. Sci.97 (1), 163–184 (2008).
   PubMed Web of Science ®Google Scholar
• Ananthapadmanabhan K . Protein-surfactant interactions. Interact Surfactants Polym. Proteins.319–365 (1993).
   Google Scholar
• Costantino HR Andya JD Nguyen PA et al. Effect of mannitol crystallization on the stability and aerosol performance of a spray-dried pharmaceutical protein, recombinant humanized anti-IgE monoclonal antibody. J. Pharm. Sci.87 (11), 1406–1411 (1998).
   PubMed Web of Science ®Google Scholar
• Grohganz H Lee Y-Y Rantanen J Yang M . The influence of lysozyme on mannitol polymorphism in freeze-dried and spray-dried formulations depends on the selection of the drying process. Int. J. Pharm.447 (1–2), 224–230 (2013).
   PubMedGoogle Scholar
• Hill JJ Shalaev EY Zografi G . Thermodynamic and dynamic factors involved in the stability of native protein structure in amorphous solids in relation to levels of hydration. J. Pharm. Sci.94 (8), 1636–1667 (2005).
   PubMed Web of Science ®Google Scholar
• Maury M Murphy K Kumar S Mauerer A Lee G . Spray-drying of proteins: effects of sorbitol and trehalose on aggregation and FT-IR amide I spectrum of an immunoglobulin. G Eur. J. Pharm. Biopharm.59 (2), 251–261 (2005).
   PubMed Web of Science ®Google Scholar
• Liao Y-H Brown MB Nazir T Quader A Martin GP . Effect of sucrose and trehalose on the preservation of the native structure of spray-dried lysozyme. Pharm. Res.19 (12), 1847–1853 (2002).
   PubMed Web of Science ®Google Scholar
• Sou T Kaminskas LM Nguyen T-H Carlberg R McIntosh MP Morton DA . The effect of amino acid excipients on morphology and solid-state properties of multi-component spray-dried formulations for pulmonary delivery of biomacromolecules. Eur. J. Pharm. Biopharm.83, 234–243 (2012).
   PubMed Web of Science ®Google Scholar
• Abdul-Fattah AM Truong-le VU Yee L et al. Drying-induced variations in physico-chemical properties of amorphous pharmaceuticals and their impact on stability (I): stability of a monoclonal antibody. J. Pharm. Sci.96 (8), 1983–2008 (2008).
   Web of Science ®Google Scholar
• Chan HK . Dry powder aerosol drug delivery-Opportunities for colloid and surface scientists. Colloids Surf. A Physicochem. Eng. Asp.284–285, 50–55 (2006).
   Web of Science ®Google Scholar
• Shoyele S a Cawthorne S . Particle engineering techniques for inhaled biopharmaceuticals. Adv. Drug Deliv. Rev.58 (9–10), 1009–1029 (2006).
   PubMed Web of Science ®Google Scholar
• Ogáin ON Li J Tajber L Corrigan OI Healy AM . Particle engineering of materials for oral inhalation by dry powder inhalers. I-Particles of sugar excipients (trehalose and raffinose) for protein delivery. Int. J. Pharm.405 (1–2), 23–35 (2011).
   PubMedGoogle Scholar
• Bosquillon C Rouxhet PG Ahimou F et al. Aerosolization properties, surface composition and physical state of spray-dried protein powders. J. Control. Release99 (3), 357–367 (2004).
   PubMed Web of Science ®Google Scholar
• White S Bennett DB Cheu S et al. EXUBERA: pharmaceutical development of a novel product for pulmonary delivery of insulin. Diabetes Technol. Ther.7 (6), 896–906 (2005).
   PubMedGoogle Scholar
• Heinemann L . The failure of exubera: are we beating a dead horse?J. Diabetes Sci. Technol.2 (3), 518–29 (2008).
   PubMedGoogle Scholar
• Mannkind Corporation . Delivery & device technology for inhalation medicines & therapy. www.mannkindtechnologies.com.
   Google Scholar
• Taluja A Youn YS Bae YH . Novel approaches in microparticulate PLGA delivery systems encapsulating proteins. J. Mater. Chem.17 (38), 4002 (2007).
   Web of Science ®Google Scholar
• Yuan W Wu F Guo M Jin T . Development of protein delivery microsphere system by a novel s/o/o/w multi-emulsion. Eur. J. Pharm. Sci.36, 212–218 (2009).
   PubMed Web of Science ®Google Scholar
• Rosca ID Watari F Uo M . Microparticle formation and its mechanism in single and double emulsion solvent evaporation. J. Control. Release99 (2), 271–280 (2004).
   PubMed Web of Science ®Google Scholar
• Grabnar PA Kristl J . The manufacturing techniques of drug-loaded polymeric nanoparticles from preformed polymers. J. Microencapsul.28 (4), 323–35 (2011).
   PubMed Web of Science ®Google Scholar
• Jovanović N Bouchard A Hofland GW Witkamp G-J Crommelin DJA Jiskoot W . Stabilization of proteins in dry powder formulations using supercritical fluid technology. Pharm. Res.21 (11), 1955–1969 (2004).
   PubMed Web of Science ®Google Scholar
• Sinha VR Trehan A . Biodegradable microspheres for protein delivery. J. Control. Release90 (3), 261–280 (2003).
   PubMed Web of Science ®Google Scholar
• Li X Kong X Shi S et al. Preparation of alginate coated chitosan microparticles for vaccine delivery. BMC Biotechnol.8 (89) (2008).
   Google Scholar
• Grenha A Rodrigues S . Pullulan-based nano particles: future therapeutic applications in transmucosal protein delivery. Ther. Deliv.4 (11), 1339–1341 (2013).
   PubMedGoogle Scholar
• Kim S Hahn S Kim M Kim D Lee Y . Development of a novel sustained release formulation of recombinant human growth hormone using sodium hyaluronate microparticles. J. Control. Release.104 (2), 323–335 (2005).
   PubMed Web of Science ®Google Scholar
• Lee ES Park K-H Kang D et al. Protein complexed with chondroitin sulfate in poly(lactide-co-glycolide) microspheres. Biomaterials28 (17), 2754–2762 (2007).
   PubMed Web of Science ®Google Scholar
• Hu L Zhang H Song W . An overview of preparation and evaluation sustained-release injectable microspheres. J. Microencapsul.30 (4), 369–382 (2013).
   PubMed Web of Science ®Google Scholar
• Mao S Guo C Shi Y Li LC . Recent advances in polymeric microspheres for parenteral drug delivery-part 1. Expert Opin. Drug Deliv.9 (9), 1161–1176 (2012).
   PubMed Web of Science ®Google Scholar
• Emami J Hamishehkar H Najafabadi AR et al. A novel approach to prepare insulin-loaded poly(lactic-co-glycolic acid) microcapsules and the protein stability study. J. Pharm. Sci.98 (5), 1712–1731 (2009).
   PubMed Web of Science ®Google Scholar
• Rafi M Singh SM Kanchan V Anish CK Panda AK . Controlled release of bioactive recombinant human growth hormone from PLGA microparticles. J. Microencapsul.27 (6), 552–560 (2010).
   PubMed Web of Science ®Google Scholar
• Bilati U Allémann E Doelker E . Strategic approaches for overcoming peptide and protein instability within biodegradable nano- and microparticles. Eur. J. Pharm. Biopharm.59 (3), 375–388 (2005).
   PubMed Web of Science ®Google Scholar
• Cawley P Wilkinson I Ross RJ . Developing long-acting growth hormone formulations. Clin. Endocrinol. (Oxf).79 (3), 305–309 (2013).
   PubMed Web of Science ®Google Scholar
• Okada H . One- and three-month release injectable microspheres of the LH-RH superagonist leuprorelin acetate. Adv. Drug Deliv. Rev.28 (1), 43–70 (1997).
   PubMed Web of Science ®Google Scholar
• Miller RA Brady JM Cutright DE . Degradation rates of oral resorbable implants (polylactates and polyglycolates): rate modification with changes in PLA/PGA copolymer ratios. J. Biomed. Mater. Res.11 (5), 711–719 (1977).
   PubMed Web of Science ®Google Scholar
• Williams GR Chatterton NP Nazir T Yu D-G Zhu L-M Brandford-White CJ . Electrospun nanofibers in drug delivery: recent developments and perspectives. Ther. Deliv., 515–533 (2012).
   PubMedGoogle Scholar
• Jia H Zhu G Vugrinovich B Kataphinan W Reneker DH Wang P . Enzyme-carrying polymeric nanofibers prepared via electrospinning for use as unique biocatalysts. Biotechnol. Prog.18 (5), 1027–1032 (2002).
   PubMed Web of Science ®Google Scholar
• Jiang H Hu Y Li Y Zhao P Zhu K Chen W . A facile technique to prepare biodegradable coaxial electrospun nanofibers for controlled release of bioactive agents. J. Control. Release108 (2–3), 237–243 (2005).
   PubMed Web of Science ®Google Scholar
• Yang Y Li X Cui W Zhou S Tan R Wang C . Structural stability and release profiles of proteins from core-shell poly (DL-lactide) ultrafine fibers prepared by emulsion electrospinning. J. Biomed. Mater. Res. A.86 (2), 374–385 (2008).
   PubMedGoogle Scholar
• Ahmad B Gunduz O Stoyanov S Pelan E Stride E Edirisinghe M . A novel hybrid system for the fabrication of a fibrous mesh with micro-inclusions. Carbohydr. Polym.89 (1), 222–229 (2012).
   PubMed Web of Science ®Google Scholar
• Jia X Zhao C Li P et al. Sustained release of VEGF by coaxial electrospun dextran/PLGA fibrous membranes in vascular tissue engineering. J. Biomater. Sci. Polym. Ed.22 (13), 1811–1827 (2011).
   PubMed Web of Science ®Google Scholar
• Khalili H Godwin A Choi J-W Lever R Khaw PT Brocchini S . Fab-PEG-Fab as a potential antibody mimetic. Bioconjug. Chem.24 (11), 1870–1882 (2013).
   PubMed Web of Science ®Google Scholar
• Rifkin RA Maggio ET Dike S Kerr DA Levy M . n-Dodecyl-β-D-maltoside inhibits aggregation of human interferon-β-1b and reduces its immunogenicity. J. Neuroimmune Pharmacol.6 (1), 158–162 (2011).
   PubMed Web of Science ®Google Scholar
• Creative Commons license . http://creativecommons.org/licenses/by-nc-nd/3.0/.
   Google Scholar